Literature DB >> 2820776

Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells.

G D Roodman1, A Bird, D Hutzler, W Montgomery.   

Abstract

Macrophages can modulate the growth of hematopoietic progenitors. We have examined the effects of tumor necrosis factor-alpha, a product of activated macrophages, on human erythroid progenitors (CFU-E, BFU-E) and the hematopoietic cell lines K562, HL60, and HEL cells. Tumor necrosis factor (TNF) significantly inhibited CFU-E and BFU-E growth at concentrations as low as 10(-11)-10(-12) M (0.2 U/ml), although erythroid colony and burst formation were not totally ablated. Preincubation of marrow samples with TNF for 15 min was sufficient to suppress erythroid colony and burst formation. Addition of TNF after the start of culture inhibited CFU-E- and BFU-E-derived colony formation if TNF was added within the first 48 h of culture. Additionally, TNF inhibited the growth of highly purified erythroid progenitors harvested from day 5 BFU-E. The colonies which formed in cultures treated with TNF were significantly smaller than those formed in control cultures. TNF (10(-8)-10(-10) M) also suppressed the growth of the hematopoietic cell lines K562, HL60, and HEL cells, with 40%-60% of the cells being sensitive to TNF. Preincubation of HL60 cells with TNF for 15 min significantly inhibited their growth. K562, HL60, and HEL cells expressed high-affinity receptors for TNF in low numbers (6000-10,000 receptors per cell). Fluorescence-activated cell sorter analysis of TNF binding to HEL cells demonstrated that the majority of these cells expressed TNF receptors. These data suggest that: (1) TNF is a rapid irreversible and extremely potent inhibitor of CFU-E, BFU-E, and hematopoietic cell lines K562, HL60, and HEL cells; (2) TNF appears to be acting on a subpopulation of erythroid cells, predominantly CFU-E, BFU-E, and possibly proerythroblasts; (3) TNF appears not to require accessory cells such as lymphocytes or macrophages to inhibit erythroid progenitors; and (4) the presence of TNF receptors on hematopoietic cells is not sufficient to confer sensitivity to TNF since the majority (80%-95%) of HEL cells express TNF receptors while only 40%-60% are inhibited by TNF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820776

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  26 in total

1.  Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells.

Authors:  R T Means; E N Dessypris; S B Krantz
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

2.  Microfluidic device capable of medium recirculation for non-adherent cell culture.

Authors:  Angela R Dixon; Shrinidhi Rajan; Chuan-Hsien Kuo; Tom Bersano; Rachel Wold; Nobuyuki Futai; Shuichi Takayama; Geeta Mehta
Journal:  Biomicrofluidics       Date:  2014-02-25       Impact factor: 2.800

Review 3.  Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease.

Authors:  M Jongen-Lavrencic; H R Peeters; G Vreugdenhil; A J Swaak
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

4.  Gene expression of cytokines suppressing hematopoietic progenitor cells in lymphoid malignancies.

Authors:  C Kawasaki; S Okamura; S Hayashi; S Kondo; M Harada; Y Niho
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha.

Authors:  J P Maciejewski; C Selleri; T Sato; H J Cho; L K Keefer; C F Nathan; N S Young
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 6.  Potential immune mechanisms associated with anemia in Plasmodium vivax malaria: a puzzling question.

Authors:  Thiago Castro-Gomes; Luiza C Mourão; Gisely C Melo; Wuelton M Monteiro; Marcus V G Lacerda; Érika M Braga
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

Review 7.  Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.

Authors:  F Morceau; M Dicato; M Diederich
Journal:  Mediators Inflamm       Date:  2010-03-01       Impact factor: 4.711

8.  Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon.

Authors:  R T Means; S B Krantz
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

9.  Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.

Authors:  G E Verhoef; P Zachée; A Ferrant; H Demuynck; D Selleslag; L Van Hove; F Deckers; M A Boogaerts
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

10.  The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.

Authors:  Min Kyoung Kim; Jae Lyun Lee; Hee Soon Cho; Sung Hwa Bae; Hun Mo Ryoo; Kyung Hee Lee; Myung Soo Hyun
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.